Clémence Astier

Clémence Astier

Auto-generated profile, based on publicly available information

Clémence Astier

The ATIP-Avenir Inserm and ERC StG (Epi)genetic Vulnerabilities in Solid Tumors and Sarcoma Laboratory, Inserm Unit UMR 981, Université Paris-Saclay, Gustave Roussy, Villejuif, France

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 October 2024 in Cancer Research
Verified
Journal Article
Open access
PDF file
AKAsuka Kawai-Kawachi
Asuka Kawai-Kawachi
MLMadison M. Lenormand
Madison M. Lenormand
CAClémence Astier
Clémence Astier
NHNoé Herbel
Noé Herbel
MCMeritxell B. Cutrona
Meritxell B. Cutrona
SPSophie Postel-Vinay
Sophie Postel-Vinay
Desmoplastic small round cell tumor (DSRCT) is an aggressive sarcoma subtype that is driven by the EWS–WT1 chimeric transcription factor. The prognosis for DSRCT is poor, and major advances in treating DSRCT have not occurred for over two decades. To identify effective therapeutic approaches to target DSRCT, we conducted a high-throughput drug sensitivity screen in a DSRCT cell line assessing chemosensitivity profiles for 79 small-molecule inhibitors. DSRCT cells were sensitive to PARP inhibitors (PARPi) and ataxia–telangiectasia and Rad3–related inhibitors (ATRi), as monotherapies and in combination. These effects were recapitulated using multiple clinical PARPi and ATRi in three biologically distinct, clinically relevant models of DSRCT, including cell lines, a patient-derived xenograft–derived organoid model, and a cell line–derived xenograft mouse model. Mechanistically, exposure to a combination of PARPi and ATRi caused increased DNA damage, G2–M checkpoint activation, micronuclei accumulation, replication stress, and R-loop formation. EWS–WT1 silencing abrogated these phenotypes and was epistatic with exogenous expression of the R-loop resolution enzyme RNase H1 in reversing sensitivity to PARPi and ATRi monotherapies. The combination of PARPi and ATRi also induced EWS–WT1–dependent cell-autonomous activation of the cyclic GMP–AMP synthase–stimulator of IFN genes innate immune pathway and cell-surface expression of PD-L1. Taken together, these findings point toward a role for EWS–WT1 in generating R-loop–dependent replication stress that leads to a targetable vulnerability, providing a rationale for the clinical assessment of PARPi and ATRi in DSRCT. Significance: EWS–WT1, the unique oncogenic driver of desmoplastic small round cell tumors, confers sensitivity to PARP and ATR inhibitors, supporting the potential of these drugs in treating patients with this aggressive sarcoma subtype.

2 January 2025
Verified
Other
Open access
AKAsuka Kawai-Kawachi
Asuka Kawai-Kawachi
MLMadison M. Lenormand
Madison M. Lenormand
CAClémence Astier
Clémence Astier
NHNoé Herbel
Noé Herbel
MCMeritxell B. Cutrona
Meritxell B. Cutrona
SPSophie Postel-Vinay
Sophie Postel-Vinay
PARPi and ATRi combination elicits DNA damage, replication stress, and genomic instability in DSRCT cells. A–D, Quantification of γH2AX (A and B) or RAD51 foci (C and D) in JN1 (A and C) or R (B and D) cells exposed to DMSO control, PARPi talazoparib (Tala), ATRi M4344, or a combination of both for 72 hours. Cisplatin was used as the positive control. A minimum of 500 nuclei was analyzed per condition. Violin plots show the absolute number of foci per nucleus. Thick line, median; thin lines, bottom and top quartiles; two-way ANOVA and post hoc Dunn test. E and F, Western blots of pCHK1, CHK1, pRPA2, RPA2, γH2AX, H2AX, and cleaved-PARP1 (cPARP) in JN1 (E) or R (F) cells exposed to DMSO control, PARPi talazoparib or olaparib, ATRi M4344 or AZD6738, or a combination of both for 48 hours. G and H, Representative immunofluorescence images (G) and quantification (H) of micronuclei-positive cells in JN1 cells exposed to DMSO control, PARPi talazoparib, ATRi M4344, or a combination of both for 72 hours. A minimum of 500 cells was analyzed per condition. Mean ± SD; n = 3; one-way ANOVA and post hoc Dunn test. Arrows, micronuclei. Scale bar, 20 μm. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001; ns, not significant.

17 June 2026
Verified
Other
Open access
AKAsuka Kawai-Kawachi
Asuka Kawai-Kawachi
MLMadison M. Lenormand
Madison M. Lenormand
CAClémence Astier
Clémence Astier
NHNoé Herbel
Noé Herbel
MCMeritxell B. Cutrona
Meritxell B. Cutrona
SPSophie Postel-Vinay
Sophie Postel-Vinay
Supplementary File containing methods, figures and uncropped membranes.

2 January 2025
Verified
Other
Open access
AKAsuka Kawai-Kawachi
Asuka Kawai-Kawachi
MLMadison M. Lenormand
Madison M. Lenormand
CAClémence Astier
Clémence Astier
NHNoé Herbel
Noé Herbel
MCMeritxell B. Cutrona
Meritxell B. Cutrona
SPSophie Postel-Vinay
Sophie Postel-Vinay
Supplementary File containing methods, figures and uncropped membranes.

2 January 2025
Verified
Other
Open access
AKAsuka Kawai-Kawachi
Asuka Kawai-Kawachi
MLMadison M. Lenormand
Madison M. Lenormand
CAClémence Astier
Clémence Astier
NHNoé Herbel
Noé Herbel
MCMeritxell B. Cutrona
Meritxell B. Cutrona
SPSophie Postel-Vinay
Sophie Postel-Vinay
PARPi and ATRi have synergistic cytotoxic effects in models of DSRCT with high PARP1 expression. A and B, PARP1 expression (A) and PARylation levels (B) as assessed by IHC in a cohort of 16 DSRCT samples, compared with those of the JN1 and R cell lines (PARP1 and PAR expression levels are shown as H-scores). Representative cases (PARP1-high vs. PARP1-low tumors; PAR-high vs. PAR-low tumors) are shown to the right, compared with JN1 and R cells. C and D, Surface plots of Bliss independence scores calculated for the talazoparib–M4344 combination in JN1 (C) and R (D) cell lines at 7 days. E, The GR_13-PDX-O model was established from the primary peritoneal tumor of a patient with DSRCT, with confirmation of EWSR1::WT1 fusion by FISH and WT1-Cter IHC (Supplementary Fig. S8). F, Surface plot of Bliss independence scores calculated for the talazoparib–M4344 combination in the GR_13 PDX-O at 7 days. Mean ± SD; n = 3. Surface plots: the x-axis and y-axis values indicate drug concentrations, and the z-axis values indicate the associated synergy score; score < −10, antagonistic interaction; score = 0, absence of interaction; score > 10, synergistic interaction. G, Schematic illustration of an in vivo therapeutic experiment performed to evaluate the antitumor effect of PARPi talazoparib and ATRi M1774 in NSG mice engrafted with JN1 xenografts. H, Therapeutic responses to drug treatment in mice harboring JN1 xenografts. Mean tumor volume ± SD; two-way ANOVA and post hoc Dunnett test. I, Tumor volume at the time of mice sacrifice. Mean ± SD; one-way ANOVA and post hoc Šídák test. *, P < 0.01; ns, not significant. Tala, talazoparib.